Off-tumor Target--beneficial Site for Antiangiogenic Cancer Therapy?

Overview

Journal Nat Rev Clin Oncol

Specialty Oncology

Date 2010 Aug 5

PMID 20683436

Citations 26

Authors

Yihai Cao

Affiliations

Soon will be listed here.

Abstract

Antiangiogenic cancer therapy is based on agents that target blood vessels of the tumor to inhibit its growth. However, experience from the clinic demonstrates that survival benefits following antiangiogenic therapy do not always correlate with tumor size and growth inhibition. Emerging evidence shows that delivery of antiangiogenic drugs might induce systemic alterations of the vasculature that modulate the function of various tissues and organs. Normalization of tissues and organs by antiangiogenic therapy may be an important mechanism underlying the survival benefits seen in patients with cancer who suffer cancer-associated systemic syndromes. This new concept has been validated in preclinical tumor models, and responses in patients have positively correlated with clinical benefits.

Citing Articles

Tumor angiogenesis and anti-angiogenic therapy.

Guo Z, Jing X, Sun X, Sun S, Yang Y, Cao Y Chin Med J (Engl). 2024; 137(17):2043-2051.

PMID: 39051171 PMC: 11374217. DOI: 10.1097/CM9.0000000000003231.

The Role of Salivary Vascular Endothelial Growth Factor A, Cytokines, and Amino Acids in Immunomodulation and Angiogenesis in Breast Cancer.

Sarf E, Dyachenko E, Belskaya L Biomedicines. 2024; 12(6).

PMID: 38927536 PMC: 11201966. DOI: 10.3390/biomedicines12061329.

Cancer-triggered systemic disease and therapeutic targets.

Cao Y Holist Integr Oncol. 2024; 3(1):11.

PMID: 38482486 PMC: 10927837. DOI: 10.1007/s44178-024-00077-w.

Spatial transcriptomics reveals heterogeneity of histological subtypes between lepidic and acinar lung adenocarcinoma.

Xie L, Kong H, Yu J, Sun M, Lu S, Zhang Y Clin Transl Med. 2024; 14(2):e1573.

PMID: 38318637 PMC: 10844893. DOI: 10.1002/ctm2.1573.

Understanding tumour endothelial cell heterogeneity and function from single-cell omics.

Zeng Q, Mousa M, Nadukkandy A, Franssens L, Alnaqbi H, Alshamsi F Nat Rev Cancer. 2023; 23(8):544-564.

PMID: 37349410 DOI: 10.1038/s41568-023-00591-5.

References

Maxwell P, Wiesener M, Chang G, Clifford S, Vaux E, Cockman M . The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999; 399(6733):271-5. DOI: 10.1038/20459. View

Longo R, Gasparini G . Challenges for patient selection with VEGF inhibitors. Cancer Chemother Pharmacol. 2007; 60(2):151-70. DOI: 10.1007/s00280-006-0403-6. View

Wick A, Schafer N, Dorner N, Schemmer D, Platten M, Bendszus M . Arterial hypertension and bevacizumab treatment in glioblastoma: no correlation with clinical outcome. J Neurooncol. 2009; 97(1):157-8. DOI: 10.1007/s11060-009-0003-5. View

OReilly M, Holmgren L, Shing Y, Chen C, Rosenthal R, Moses M . Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994; 79(2):315-28. DOI: 10.1016/0092-8674(94)90200-3. View

Ravaud A, Sire M . Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer. Ann Oncol. 2009; 20(5):966-7. DOI: 10.1093/annonc/mdp201. View

Saif M, Longo W, Israel G . Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer. Clin Colorectal Cancer. 2008; 7(2):144-8. DOI: 10.3816/CCC.2008.n.020. View

Kornguth S . Neuronal proteins and paraneoplastic syndromes. N Engl J Med. 1989; 321(23):1607-8. DOI: 10.1056/NEJM198912073212310. View

Hedlund E, Hosaka K, Zhong Z, Cao R, Cao Y . Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature. Proc Natl Acad Sci U S A. 2009; 106(41):17505-10. PMC: 2752403. DOI: 10.1073/pnas.0908026106. View

Ebos J, Lee C, Christensen J, Mutsaers A, Kerbel R . Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A. 2007; 104(43):17069-74. PMC: 2040401. DOI: 10.1073/pnas.0708148104. View

10.

Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C . Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol. 2008; 20(2):227-30. DOI: 10.1093/annonc/mdn637. View

11.

Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z . Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999; 13(1):9-22. View

12.

Aoyagi T, Mori I, Ueyama Y, Tamaoki N . Sinusoidal dilatation of the liver as a paraneoplastic manifestation of renal cell carcinoma. Hum Pathol. 1989; 20(12):1193-7. DOI: 10.1016/s0046-8177(89)80011-5. View

13.

Kappers M, van Esch J, Sleijfer S, Danser A, van den Meiracker A . Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects. J Hypertens. 2009; 27(12):2297-309. DOI: 10.1097/HJH.0b013e3283309b59. View

14.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View

15.

Azizi M, Chedid A, Oudard S . Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med. 2008; 358(1):95-7. DOI: 10.1056/NEJMc072330. View

16.

Shinojima T, Oya M, Takayanagi A, Mizuno R, Shimizu N, Murai M . Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha. Carcinogenesis. 2006; 28(3):529-36. DOI: 10.1093/carcin/bgl143. View

17.

Poon R, Fan S, Wong J . Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol. 2001; 19(4):1207-25. DOI: 10.1200/JCO.2001.19.4.1207. View

18.

Jain R . Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001; 7(9):987-9. DOI: 10.1038/nm0901-987. View

19.

Nakayama T, Mutsuga N, Tosato G . Effect of fibroblast growth factor 2 on stromal cell-derived factor 1 production by bone marrow stromal cells and hematopoiesis. J Natl Cancer Inst. 2007; 99(3):223-35. DOI: 10.1093/jnci/djk031. View

20.

Tenan M, Fulci G, Albertoni M, Diserens A, Hamou M, Feige J . Thrombospondin-1 is downregulated by anoxia and suppresses tumorigenicity of human glioblastoma cells. J Exp Med. 2000; 191(10):1789-98. PMC: 2193158. DOI: 10.1084/jem.191.10.1789. View